Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer

Anti-Cancer Drugs

Volumn 10, Issue 8, 1999, Pages 729-733

  Hartmann, J T ^a   Quietzsch, D ^b   Daikeler, T ^a   Kollmannsberger, C ^a   Mayer, F ^a   Kanz, L ^a   Bokemeyer, C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

Author keywords

Advanced gastric cancer; Continuous infusion; Mitomycin C; Salvage chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; PACLITAXEL; PREDNISONE;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFECTION; LEUKOPENIA; LUNG DISEASE; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PAIN; PRIORITY JOURNAL; REMISSION; SALVAGE THERAPY; SKIN TOXICITY; STOMACH CANCER; THROMBOCYTOPENIA; VASCULAR DISEASE; VOMITING;

EID: 0033398056     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199909000-00006     Document Type: Article

References (28)

1. 1. Dorr RT. New findings in the pharmacokinetic, metabolic and drug-resistance aspects of mitomycin C. Semin Oncol 1988; 15: 32-41 .
2. 2. Doroshow JH. Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones. Proc Natl Acad Sci USA 1986; 83: 4514-8.
3. 3. Dusre L, Rayagopalan S, Eliot HM, Covey JM, Sinha BK. DNA interstrand cross-link and free radical formation in a human multidrug-resistant cell line for mitomycin C and its analogues. Cancer Res 1990; 50: 648-52.
4. 4. Pritsos CA, Sarotelli AC Generation of reactive oxygen radicals through bioactivation of mitomycin C antibiotics. Cancer Res 1986; 46: 3528-32.
5. 5. Moertel CG. Clinical management of advanced gastrointestinal cancer. Cancer 1975; 36: 675-82.
6. 6. Comis R. Integration of chemotherapy into combined modality treatment of solid tumours. Cancer Treat Rev 1974; 1: 22-33.
7. 7. Hartmann JT, Harstrick A, Daikeler T, et al. Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. Anti-Cancer Drugs 1998; 9: 427-31.
8. 8. Löffler TM, Weber FW, Hausamen TU. Klinische Erfahrungen mit der ambulanten Dauerinfusion von Mitomycin C. Tumordiagnostik & Therapie 1992; 12: 132-5.
9. 9. Machover D, Goldschmidt E, Chollet P. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986; 4: 685-96.
10. 10. Kaplan EL, Maier P. Non-parametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457-81.
11. 11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
12. 12. Reitemeier RJ, Moertel CG, Hahn RG. Combination chemotherapy in gastrointestinal cancer. Cancer Res 1970; 30: 1425-8.
13. 13. Moertel CG, Reitemeier RJ, Hahn RG. Mitomycin C in advanced gastrointestinal cancer. J Am Med Ass 1968; 204: 1045-8.
14. 14. Wils J, Bleiberg H, Dalesio O, et al EORTC group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 1986; 4: 1799-803.
15. 15. Wilke H, Preusser P, Fink U, et al. New developments in the treatment of gastric carcinoma. Semin Oncol 1990; 17 (suppl 2): 61-70.
16. 16. Lerner A, Gonin R, Steele GD Jr, Mayer RJ. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 1992; 10: 536-40.
17. 17. Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541-8.
18. 18. Stahl M, Vanhoefer U, Fink U, et al. Phase II Study of weekly high-dose 5-fluorouracil and folinic acid plus biweekly alternating cisplatin and epirubicin (FUFACE) in patients with advanced gastric carcinoma. Onkologie 1996; 19: 416-8.
19. 19. Bokemeyer C, Hartmann JT, Lampe CS, et al. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol 1997 24 (suppl 19): 96-100.
20. 20. Roelofs EJM, Wagener DJTh, Conroy Th, et al. Phase II study of sequential high-dose methotrexate (MTX and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer. Ann Oncol 1993; 4: 426-8.
21. 21. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol; 1999; 17: 319-23.
22. 22. Vanhoefer U, Wilke H, Weh HJ, et al. Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 1994; 5: 850-1.
23. 23. Di Bartolomeo M, Bajetta E, Somma L, et al. Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. Oncology 1996; 53: 54-7.
24. 24. Wilke H, Vanhoefer U, Harstrick A. Phase II study of doxetaxel as salvage chemotherapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1998; 17: 305 (abstr 1177).
25. 25. Cascinu S, Graziano F, Cardarelli N, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anti-Cancer Drugs 1998; 9: 307-10.
26. 26. Adenis A, Leriche N, Pion JM, Vanlemmens L, Bonneterre J. Ineffectiveness of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX regimen) as a salvage therapy in advanced colorectal cancers and other gastrointestinal tumors. Anticancer Res 1996; 16: 2063-8.
27. 27. Rougier P, van Pottelsberghe C, Kok T, et al. Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group). Eur J Cancer 1996; 32A: 1432-3.
28. 28. Allum WH, Hallissey MT, Kelly A. Adjuvant chemotherapy in operable gastric cancer. Lancet 1989; i: 571-4.